Navigation Links
According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators
Date:3/5/2009

LONDON, March 5 /PRNewswire/ -- The demand for a reliable, non-invasive, efficient and cost-effective technology that improves patients' lifestyles is boosting interest in bone growth and spinal fusion stimulators in Europe. The market is however still small, as clinicians have felt that the technology needs to be better proved. This situation is changing though, as companies introduce innovative products with clinical studies and research papers to substantiate the efficacy of their offerings.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), European Bone Growth and Spinal Fusion Stimulators Markets, finds that the markets earned revenues of $73.5 million in 2007 and estimates this to reach $118.0 million by 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European bone growth and spinal fusion stimulators markets, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

"An increasing number of scientific research studies support these technologies," notes a Frost & Sullivan analyst. "Each year, manufacturers and independent researchers are publishing more papers, describing in greater detail how stimulation has beneficial effects and which types of patients can best benefit from this treatment."

There is still a great deal of debate among orthopaedicians about what dosage of stimulation is optimal for a given patient with a given condition. However, most of them now agree that the technology is able to produce good results in most selected patients.

Reimbursement still remains an issue for the market, but some hospitals are now including bone growth stimulation in their budgets. Although used primarily for treating worst-case failures, they are gradually gaining acceptance as an alternative to non-union surgery.

"This technology has met with much resistance in Europe, but as clinical experience is gained, bone growth stimulation will be regarded as a good option at the surgeon's disposal in the future," states the analyst. "Patients tend to get coverage from private or public insurance for other treatments, yet for bone and spinal fusion stimulators no coverage is offered, giving patients the impression that one treatment is better or more accepted than the other."

European Bone Growth and Spinal Fusion Stimulators Markets is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European Markets for Bone Grafts and Bone Cements and Issues and Trends in Infection Control Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

European Bone Growth and Spinal Fusion Stimulators Markets

M281

    Contact:
    Katja Feick
    Corporate Communications
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com

   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
3. Sexual function affected by stem cell transplant according to long-term study
4. Early treatment of children with bilateral amblyopia essential, according to multisite study
5. Americans consider global warming an urgent threat, according to poll
6. Red wine and grape juice help defend against food-borne diseases, according to MU researchers
7. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
8. 2007 InfantSEE(R) Data Magnifies the Need for Early Eye and Vision Screenings for Infants, According to American Optometric Association
9. Survival of newborns with abdominal holes differs according to hospital, Hopkins research shows
10. Gateway Health Plan Ranked Again Among Americas Best Health Plans According to U.S. News & World Report, NCQA
11. Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... research and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money ... be packaged with the April edition of American Veterinarian™. , “We ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , ... pursue the recent RNA methylation “gold rush” with their established portfolio of optimized ... characteristics of N6-methyladenosine, or m6A , RNA methylation has received a new ...
(Date:3/27/2017)... Los Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... for men with prostate cancer, including all stages, is more than 95%. Once the ... drops drastically to less than 30%. To find out how to avoid this latter ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Harris Communications, ... of hearing, is bringing its latest products to the Deaf Seniors of America Conference, ... have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
(Date:3/27/2017)... , March 27, 2017 ... clinical-stage pharmaceutical company specializing in the development of cannabinoid-based ... offering in the United States ... ADS representing 40 ordinary shares of the Company, ... addition, Therapix has granted the underwriters a 45-day ...
Breaking Medicine Technology: